DR6 Stock Overview
A biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DR6 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.10 |
| 52 Week High | US$28.20 |
| 52 Week Low | US$13.06 |
| Beta | 0.41 |
| 1 Month Change | 4.99% |
| 3 Month Change | 10.61% |
| 1 Year Change | -39.47% |
| 3 Year Change | -24.24% |
| 5 Year Change | -58.52% |
| Change since IPO | 195.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| DR6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -2.6% | -2.0% |
| 1Y | -39.5% | -13.2% | 6.8% |
Return vs Industry: DR6 underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: DR6 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| DR6 volatility | |
|---|---|
| DR6 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DR6 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DR6's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 620 | Catherine Owen Adams | www.acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| DR6 fundamental statistics | |
|---|---|
| Market cap | €2.70b |
| Earnings (TTM) | €123.48m |
| Revenue (TTM) | €892.90m |
22.2x
P/E Ratio3.1x
P/S RatioIs DR6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DR6 income statement (TTM) | |
|---|---|
| Revenue | US$929.24m |
| Cost of Revenue | US$347.19m |
| Gross Profit | US$582.05m |
| Other Expenses | US$453.54m |
| Earnings | US$128.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.77 |
| Gross Margin | 62.64% |
| Net Profit Margin | 13.83% |
| Debt/Equity Ratio | 0% |
How did DR6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 16:13 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ACADIA Pharmaceuticals Inc. is covered by 37 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Joel Beatty | Baird |
| Ishan Majumdar | Baptista Research |